• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Lee Landenberger

Articles by Lee Landenberger

The Asia Pacific region: Poised for gains, if ...

Sep. 4, 2019
By Lee Landenberger
The Asia Pacific region (APAC) is vast and awash with varied economies, languages, governments and ambitions. That's the backdrop for its dramatic underperformance compared to the West's pharmaceutical innovations. Yet plenty of opportunities exist, along with a healthy dose of uncertainty, according to the first Pharmaceutical Innovation in the APAC region report, published by Clarivate Analytics plc.
Read More

Aridis study failure ends development of AR-105

Sep. 4, 2019
By Lee Landenberger
Following its phase II stumble of AR-105, Aridis Pharmaceuticals Inc. is dropping its development of the IgG1 monoclonal antibody. The study failed to meet its primary endpoint of showing superiority in clinical cure rates compared to placebo for treating ventilator-associated pneumonia caused by gram-negative Pseudomonas aeruginosa.
Read More

Standing at the crossroads of people and technology

Aug. 30, 2019
By Lee Landenberger
In retrospect, it seems inevitable that an algorithm would be appointed to a board of directors. Hong Kong-based Deep Knowledge Ventures named Vital (an acronym for Validating Investment Tool for Advancing Life Sciences) to its board five years ago and credits it with making better decisions than its fellow members, humans all.
Read More

At the crossroads of people and technology

Aug. 30, 2019
By Lee Landenberger
In retrospect, it seems inevitable that an algorithm would be appointed to a board of directors. Hong Kong-based Deep Knowledge Ventures named Vital (an acronym for Validating Investment Tool for Advancing Life Sciences) to its board five years ago and credits it with making better decisions than its fellow members, humans all.
Read More

Astrazeneca's anifrolumab for lupus meets primary endpoint

Aug. 30, 2019
By Lee Landenberger
With a year-old phase III failure dogging it, Astrazeneca plc's phase III Tulip 2 clinical trial of anifrolumab for treating systemic lupus erythematosus (SLE) met its primary endpoint by reducing disease activity vs. placebo.
Read More

The Asia Pacific region: Poised for gains, if ...

Aug. 29, 2019
By Lee Landenberger
The Asia Pacific region (APAC) is vast and awash with varied economies, languages, governments and ambitions. That's the backdrop for its dramatic underperformance compared to the West's pharmaceutical innovations. Yet plenty of opportunities exist, along with a healthy dose of uncertainty, according to the first Pharmaceutical Innovation in the APAC region report, published by Clarivate Analytics plc.
Read More

Across the great (skills) divide

Aug. 26, 2019
By Lee Landenberger

Across the great (skills) divide

Aug. 26, 2019
By Lee Landenberger
Winter is coming to the artificial intelligence industry. While it's springtime for investment and technological advancement, gray skies hover over the talent pool.
Read More

Oncorus has $79.5M chorus in oversubscribed series B

Aug. 22, 2019
By Lee Landenberger
Oncorus Inc. plans to use its oversubscribed $79.5 million series B financing getting its lead candidate, ONCR-177, into the clinic early next year.
Read More

Astrazeneca's phase III Farxiga trial meets primary endpoint; hits cardiovascular target

Aug. 21, 2019
By Lee Landenberger
Astrazeneca plc's Farxiga (dapagliflozin), already the company's fifth best-selling product, now has a heart-failure component. The SGLT2 inhibitor met its phase III study's primary composite endpoint in reducing cardiovascular death or the worsening of heart failure compared to placebo in patients with reduced ejection fraction on standard-of-care treatment, including those with and without type 2 diabetes.
Read More
Previous 1 2 … 133 134 135 136 137 138 139 140 141 … 147 148 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 18, 2025.
  • Multiple myeloma and antibodies

    Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

    BioWorld
    The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...
  • Rexulti

    Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study

    BioWorld
    In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress...
  • Atai Therapeutics discovers new 5-HT2A receptor partial agonists

    BioWorld Science
    Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe